Beyond Low-Density Lipoprotein Cholesterol

• Published in: Journal of the American College of Cardiology Vol. 50; no. 18; pp. 1735 - 1741
• Main Authors: Mudd, James O., MD, Borlaug, Barry A., MD, Johnston, Peter V., MD, Kral, Brian G., MD, MPH, Rouf, Rosanne, MD, Blumenthal, Roger S., MD, Kwiterovich, Peter O., MD
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 30.10.2007
• Subjects: Cardiovascular; Internal Medicine; coronary artery disease; apo; apolipoprotein; CE; GGE; LDL-C; low-density lipoprotein cholesterol; CAD; triglycerides; nuclear magnetic resonance; total cholesterol; gradient gel electrophoresis; Lp(a); lipoprotein (a); TC; HDL-C; total number of low-density lipoprotein particles; NMR; DGU; TG; cholesteryl esters; high-density lipoprotein cholesterol; LDL-P; density-gradient ultracentrifugation
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2007.07.045

Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease James O. Mudd, Barry A. Borlaug, Peter V. Johnston, Brian G. Kral, Rosanne Rouf, Roger S. Blumenthal, Peter O. Kwiterovich, Jr Recently many clinical trials have shown reductions in recurrent cardiovascular events with aggressive lipid lowering therapy targeting low-density lipoprotien-cholesterol (LDL-C) levels. However LDL-C alone does not give a complete picture of all the atherogenic low-density lipoprotein particles (LDL-P). Measurement of apoliprotein B (apoB) is a better estimate of LDL-P, and has been shown to be a better predictor of recurrent cardiovascular events compared to LDL-C and non–high-density lipoprotein-cholesterol. While LDL-P can be measured with additional lipoprotein testing methods, measurement of apoB is readily available and may help to modify aggressive lipid reduction therapy in addition to standard lipoprotein measures.